Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment

INTRODUCTION: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or cyclophosphamide treatment from those for whom treatment failed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Mazen, Pouliot, Yannick, Hartmann, Bjoern, Dunn, Patrick, Thomson, Elizabeth, Wiser, Jeffrey, Butte, Atul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576403/
https://www.ncbi.nlm.nih.gov/pubmed/26387933
http://dx.doi.org/10.1186/s13075-015-0778-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576403/
https://www.ncbi.nlm.nih.gov/pubmed/26387933
http://dx.doi.org/10.1186/s13075-015-0778-z

Ejemplares similares